Celldex Therapeutics, Inc. (CLDX)

Several key events have impacted Celldex Therapeutics' stock price in the past six months. Celldex announced the early completion of enrollment for its Phase 3 CSU studies in February 2026. In December 2025, Celldex initiated a global Phase 3 study in cold urticaria and symptomatic dermographism. In April 2026, Celldex closed an underwritten public offering, generating gross proceeds of approximately $345 million. On May 7, 2026, Celldex reported its financial results for the first quarter ended March 31, 2026, reporting a net loss of $78.7 million. In April 2026, Barclays upgraded Celldex Therapeutics from "Sell" to "Buy" and raised its price target, Goldman Sachs maintained a "Neutral" rating in March 2026, and Wall Street Zen upgraded Celldex from a "strong sell" to a "sell" rating in May 2026.

As a clinical-stage biopharmaceutical company, Celldex Therapeutics, Inc. does not currently have commercialized products generating significant revenue, and therefore, traditional product demand seasonality is not applicable. However, based on past performance, November has shown the highest probability of positive returns for CLDX stock, while May has a lower probability of positive returns, and December has historically shown a high probability for decline.

Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on mast cell biology and developing therapeutic antibodies. They aim to create antibody-based treatments for severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. Their pipeline focuses on monoclonal and bispecific antibodies, with lead product candidate barzolvolimab (CDX-0159) under investigation for various mast cell-driven conditions and CDX-622 in development for inflammatory and fibrotic disorders.

Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey, which serves as its main operational hub. The company also maintains other office locations within the United States, including New Haven, Connecticut, Fall River, Massachusetts, and Needham, Massachusetts.

Celldex Therapeutics' brand reputation has been shaped by its progress in clinical development and financial activities. The early completion of enrollment in its Phase 3 CSU studies and positive Phase 2 clinical trial data for barzolvolimab have been positive factors. The successful $345 million public offering also reflects investor confidence. Overall, the company's reputation appears to be positive, driven by promising clinical trial results and strategic financial management.

Celldex Therapeutics, Inc. has a mixed ownership structure comprising institutional, insider, and retail investors. As of May 7, 2026, the company had 195 institutional owners and shareholders holding a total of 72,342,435 shares. The largest individual shareholder is Thomas S. Paluck, who owns 7.63 million shares, representing 11.47% of the company.